About: Current Strategies for Inhibition of Chikungunya Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Current Strategies for Inhibition of Chikungunya Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Current Strategies for Inhibition of Chikungunya Infection
Creator	Chattopadhyay, Soma Subudhi, Bharat Kumar, Abhishek Mishra, Priyadarsee
source	Medline; PMC
abstract	Increasing incidences of Chikungunya virus (CHIKV) infection and co-infections with Dengue/Zika virus have highlighted the urgency for CHIKV management. Failure in developing effective vaccines or specific antivirals has fuelled further research. This review discusses updated strategies of CHIKV inhibition and provides possible future directions. In addition, it analyzes advances in CHIKV lifecycle, drug-target development, and potential hits obtained by in silico and experimental methods. Molecules identified with anti-CHIKV properties using traditional/rational drug design and their potential to succeed in subsequent stages of drug development have also been discussed. Possibilities of repurposing existing drugs based on their in vitro findings have also been elucidated. Probable modes of interference of these compounds at various stages of infection, including entry and replication, have been highlighted. The use of host factors as targets to identify antivirals against CHIKV has been addressed. While most of the earlier antivirals were effective in the early phases of the CHIKV life cycle, this review is also focused on drug candidates that are effective at multiple stages of its life cycle. Since most of these antivirals require validation in preclinical and clinical models, the challenges regarding this have been discussed and will provide critical information for further research.
has issue date	2018-05-03(xsd:dateTime)
bibo:doi	10.3390/v10050235
bibo:pmid	29751486
has license	cc-by
sha1sum (hex)	4b56a4d08058ec9ffb1c68e42f1cf3a723d4b822
schema:url	https://doi.org/10.3390/v10050235
resource representing a document's title	Current Strategies for Inhibition of Chikungunya Infection
has PubMed Central identifier	PMC5977228
has PubMed identifier	29751486
schema:publication	Viruses
resource representing a document's body	covid:4b56a4d08058ec9ffb1c68e42f1cf3a723d4b822#body_text
is schema:about of	named entity 'MOLECULES' named entity 'UPDATED' covid:arg/4b56a4d08058ec9ffb1c68e42f1cf3a723d4b822 named entity 'CHIKV' named entity 'preclinical' named entity 'Zika virus' named entity 'vaccines' named entity 'CHIKV' named entity 'CHIKV' named entity 'brain cells' named entity 'exact mechanism' named entity 'infection' named entity 'anthranilic acid derivatives' named entity 'virus' named entity 'CHIKV' named entity 'ivermectin' named entity 'CHIKV' named entity 'antiviral' named entity 'RIG-I' named entity 'hybridization' named entity 'endoplasmic reticulum' named entity 'CHIKV' named entity 'CHIKV' named entity 'ZIKV' named entity 'oxidoreductases' named entity 'CHIKV' named entity 'antiviral' named entity 'antiviral' named entity 'PKC' named entity 'rocaglamide' named entity 'bryostatin 1' named entity 'gene expression' named entity 'antimalarial drug' named entity 'CHIKV' named entity 'baicalin' named entity 'molecule' named entity 'CHIKV' named entity 'membrane fusion' named entity 'CHIKV' named entity 'CLK1' named entity 'multiplicity of infection' named entity 'sialic acid' named entity 'molecular docking' named entity '2-furoic acid' named entity 'IFN-α' named entity 'infection' named entity 'IFN-α/β' named entity 'drug resistance' named entity 'cytotoxicity' named entity 'quercetagetin' named entity 'viral infections' named entity 'orally active' named entity 'hepatitis C virus' named entity 'Herbal drug' named entity 'infection' named entity 'Pentacyclic triterpenoids' named entity 'replication cycle' named entity 'up-regulation' named entity 'ethyl acetate' named entity 'nsP4' named entity 'medicinal properties' named entity 'nsP3' named entity 'NSAID' named entity 'antiviral' named entity 'molecule' named entity 'toxicity' named entity 'methyl' named entity 'CHIKV' named entity 'Poly I:C' named entity 'CHIKV' named entity 'PKC' named entity 'EGCG' named entity 'microbes' named entity 'replicon' named entity 'protease' named entity 'Hsp90' named entity 'terpenoids' named entity 'nsP2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software